The human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) is trans activated by interactions between the virus-encoded trans activator Tat and its cognate TAR RNA stem-loop, which is located at the 5' end of all viral transcripts. This interaction is essential for high levels of viral gene expression, replication, and cellular cytopathology (15) . By comparing sequences between Tats of different lentiviruses, Tat of HIV-1 was divided into five structural domains, which are called N-terminal (prolinerich), cysteine-rich, core, basic (arginine-rich), and C-terminal domains (4). Whereas core and basic sequences are most conserved between Tats, greater differences are observed in their N-and C-terminal extensions (7) . Since the N-terminal 47 amino acids, which contain N-terminal, cysteine-rich, and core domains, when fused to heterologous RNA-and DNAbinding proteins increase expression from hybrid HIV-1 LTRs with appropriate target sequences, they represent the activation domain of Tat (20, 22) . However, domains of Tat that are required for interactions with TAR RNA in vivo have not been defined.
In vitro studies demonstrated that a nonapeptide, which contains only the arginine-rich amino acids from positions 48 to 57 in Tat, binds to the 5' bulge in TAR RNA stem-loop (3, 8, 19) . Surprisingly, binding coefficients of these short peptides were similar to those of the full-length protein (26) . This basic domain is also absolutely required for trans activation in vivo (2) . However, the precise sequence of arginines is unimportant, since only one arginine in the context of eight basic amino acids supported trans activation (2) . Furthermore, basic sequences from Rev and bacteriophage N protein could functionally replace the basic domain of Tat (23) . Although 
MATERIALS AND METHODS
Plasmid constructions. pHIVSCAT and pSVTAT were described previously (20 (20) . pSVTATRVAMCP was constructed by ligating the PstI-SacI fragment of pSVTATRVAM into the PstI-SacI sites of pSVTATCP. In this construction, R17 coat protein was fused to the C-terminus Tat containing an insertion of 11 amino acids. All constructions resulted in proteins that maintained correct reading frames. pH3/ TAR-12 and pH3/ASTAR-12 were as previously described (12) .
Transient expression and CAT enzymatic assays. HeLa cells were transfected with 10 ,ug of total DNA and 250 ,ug of DEAE-dextran per ml as described previously (20 (2, 3, 6, 26) . If these basic residues also represent an independent TAR-interactive domain in vivo, they should function when separated from the N-terminal activation domain of Tat. In this scenario, the boundary between functional activation and binding domains should be between structural core and basic domains or somewhere in the core domain of Tat. To test this hypothesis, we constructed several mutants of Tat (Fig. 1) . In pSVTATRV and pSVTATRI, four amino acids were inserted between core and basic domains and five amino acids were inserted into the core domain, respectively. Inserted amino acids were chosen at random, and introduced sequences created convenient restriction endonuclease sites (Fig. 1 ). These two plasmids were then cotransfected with pHIVSCAT, which contains the HIV-1 LTR linked to the CAT reporter gene, into HeLa cells.
Whereas cotransfections of pHIVSCAT with pSVTAT resulted in 272-fold trans activation, cotransfections of pHIVSCAT with pTATRV and pTATRI yielded 29% of wild-type levels and no trans activation, respectively ( Fig.  1 ). This initial result suggested that the basic domain can interact independently with TAR but that core sequences form part of the activation domain. However, if the argininerich domain is indeed independent and separable from the activation domain, then Tat should still function when more amino acids are inserted between core and basic domains. To test this hypothesis, two more mutants of Tat were constructed, pSVTATRVAM and pSVTATRVAA, which contained insertions of 11 and 30 amino acids between core and basic domains, respectively (Fig. 2) . However, cotransfections of pSVTATRVAM and pSVTATRVAA with pHIVSCAT resulted in only 2.1 and 0.01% of wild-type levels of trans activation (Fig. 2) . Since in these two mutants the N-terminal activation domain was intact (20, 22) However, to exclude the possibility that inserted amino acids in pSVTATRVAM and pSVTATRVAA interfered with the function of the activation domain of Tat, three additional mutants of Tat were constructed. Although pSVTAT2XCS, pSVTAT2XCM, and pSVTAT2XCA contained insertions of 10 to 32 amino acids between basic and core domains, these insertions represented duplications from positions 19 to 47 of Tat (Fig. 3) . Moreover, in these three mutants of Tat, the Fig. 1 . Below the diagram of structural domains of Tat are depicted four effectors: wild-type Tat (pSVTAT) and three mutant Tats with progressively larger insertions of amino acids from Tat. pSVTAT2XS, pSVTAT2 XCM, and pSVTAT2XCA contain 10 (4 random and 6 from Tat), 17 (5 random and 12 from Tat), and 32 (3 random and 29 from Tat) additional residues between core and basic domains, respectively. While random amino acids are depicted as larger letters, residues from Tat are given in the smaller script. Next to the numbers of additional amino acids are given their positions in Tat. These results are representative of three experiments done in triplicate.
activation domain was intact (20, 22) . Since increases in CAT activities were less than 5% of wild-type levels, pSVTAT2XCS, pSVTAT2XCM, and pSVTAT2XCA also could not trans activate the HIV-1 LTR (Fig. 3) . Actually, levels of trans activation declined with larger insertions. It should be noted that although core sequences were duplicated in pSVTAT2XCM, and core and cysteine-rich domains were duplicated in pSVTAT2XCA, these sequences surrounding the basic domain were still not sufficient for interactions between Tat and TAR. In other words, the entire N-terminal activation domain must be placed next to the basic domain for interactions between Tat and TAR in vivo.
Insertions between activation and basic domains of Tat do not affect the function of the activation domain. To demonstrate conclusively that the N-terminal activation domain was not influenced by these insertions and that their defects were due solely to their inability to interact with TAR, a mutant Tat with an insertion of 11 amino acids (pSVTAT RVAM) was also fused to the coat protein of bacteriophage R17 (pTATRVAMCP; Fig. 4 ). Since this hybrid protein contained a heterologous RNA-binding domain, effects of insertions in Tat could be evaluated independently of interactions between Tat and TAR. pHIVSRCAT, in which the operator of bacteriophage R17, which is the RNA-binding site of the coat protein, replaced TAR in pHIVSCAT, was used as the substituted target.
Although cotransfections of pHIVSCAT and pSVTATR VAM resulted in only 2.1% of wild-type levels of trans activation, cotransfections of pTATRVAMCP and pHIVSR-CAT resulted in 132-fold trans activation, 2-fold higher than that observed with our previous hybrid Tat-coat protein (pSVTATCP) and this substituted target (pHIVSRCAT; Fig.  4) (20) . Moreover, unlike pSVTATCP, pTATRVAMCP could not trans activate the wild-type HIV-1 LTR (pHIVS CAT; data not presented). These results demonstrate that the activation domain not only functions in these insertional mutants of Tat but also functions better when separated from Fig. 2 (12, 24) . Further mapping of sequences in TAR decoys revealed that both the 5' bulge and the loop of the stem-loop in TAR are required for this competition. Moreover, these TAR decoys are thought to function by sequestering either Tat, cellular TAR RNA-binding proteins, which might be required for interactions between Tat and TAR, or both (12, 24) . If separation between core and basic domains of Tat affected interactions between Tat and TAR, then the ability of pTATRVAMCP to trans activate the HIV-1 LTR via interactions between the coat protein and operator of bacteriophage R17 should not be inhibited by TAR decoys (Fig.  5) . To test this hypothesis, we performed experiments in which hybrid effectors and targets were cotransfected with plasmids that directed the synthesis of 12 contiguous TAR transcripts in either the sense or antisense orientation (pH1/ TAR-12 or pHO/ASTAR-12; Fig. 5) (12) . Whereas cotransfections of pHB/TAAR-12, but not pHP/ASTAR-12, resulted in 17% of levels of trans activation of pSVTATCP, which contains Tat sequences from positions 1 to 67 fused to the coat protein (20) , neither plasmid reduced the activity of pTATRVAMCP, which contains the insertion of 11 amino acids between activation and basic domains of Tat. Thus, our insertions between core and basic domains of Tat affected only interactions between Tat and TAR. We conclude that the basic domain of Tat does not interact with TAR even in the context of the entire cysteine-rich, core, and C-terminal domains and that the entire N-terminal activation domain must be juxtaposed to the basic domain of Tat for these interactions. (2, 3, 8, 14, 19, 25 Since the basic domain of Tat is involved in the binding of the bulge of TAR RNA, interactions between the central loop of TAR and Tat must be different. Our study suggests that these could represent associations between cellular proteins that bind to the central loop of TAR and the activation domain of Tat. Since the activation domain itself contains only 48 amino acids, this cellular protein could also be the transcriptional effector of Tat. Such a scenario has been observed with bacteriophage X; in this case, bacterial NusA protein not only is required for productive interactions between N and the nutB stem-loop, which is the RNA target of the N protein, but also forms the link between N and core RNA polymerase (16, 17) . The end result of these interactions is antitermination of bacteriophage X transcription, which is similar to effects of Tat on processivity or transcriptional elongation in HIV-1. Alternatively, two to several proteins interact with the activation domain of Tat; one increases interactions between Tat and TAR, and the other affects transcription. That increased distance between activation and basic domains of Tat interferes more with interactions between Tat and TAR than with the activation of transcription would tend to favor the latter hypothesis. However, it is also possible that interactions between this cellular protein that associates with Tat are stronger with RNA polymerase II than with the central loop of TAR or cellular proteins that interact with it. Moreover, it is unlikely that these cellular proteins are either TRP-185/TRP-1 or TRP-2, which are complexes of proteins that bind to the central loop or the 5' bulge of TAR, respectively (11, 21) .
Although both of these proteins can increase rates of transcription from the HIV-1 LTR, both also displace the binding of Tat to TAR in vitro (11, 21) . Further binding studies with Tats of different lentiviruses and the isolation and characterization of cellular proteins that bind to Tat may discriminate between these possibilities.
